1	A cross-sectional questionnaire-based landscaping of female infertility reveals
2	genital Infections as a major contributor to reproductive tract anomalies,
3	menstrual disorders, and infertility
4	
5	Naresh Patnaik ¹ , Uttam Sarkar ² , Malathi Jojula ³ , Hema Vaddiraju ⁴ , Ruchi Jain Dey ^{1, *}
6	
7	Author Affiliations:
8	¹ Department of Biological Sciences, BITS Pilani, Hyderabad Campus, Telangana
9	State- 500 078, India
10	² West Bengal University of Animal and Fishery Sciences, Department of Animal
11	Genetics and Breeding, West Bengal – 700037, India
12	³ Department of Microbiology, Sri Shivani College of Pharmacy, Mulugu Road,
13	Warangal, Telangana State – 506002, India
14	⁴ Curewell Hospital, Srinivasa Colony, Warangal, Telangana State – 506007, India
15	
16	*Corresponding author
17	Email for correspondence: ruchij80@hyderabad.bits-pilani.ac.in

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

19 Abstract

Objectives: Female infertility is a global health concern. The association of genital infections with female infertility is neglected due to their chronic but asymptomatic nature. Lack of routine diagnosis and delay in treatment further causes intractable pathological sequalae and consequential infertility. This study aims to identify the most significant prognostic symptoms of genital infection(s) that correlate strongly with reproductive tract anomalies, menstrual disorders, and infertility.

Methods: We designed a detailed questionnaire and conducted a cross-sectional study with 100 female subjects, categorized into infertile (n1 = 62) and healthy groups (n2 = 38). The data collected was documented and statistically analyzed.

Results: This study highlights an early onset of infertility (21-30 years). Almost 27% 29 of the infertile subjects are symptomatic for genital infections and ~42% exhibit 30 menstrual irregularities. Polycystic ovarian syndrome/disease (PCOS/PCOD, ~30%), 31 are observed to be the most predominant disorders followed by endometrial disorders 32 (~10%) and tubal damage (~8%) in infertile subjects. A multivariate correlation analysis 33 revealed a highly significant ($p \le 0.05$) and strong association ($0.15 < \Phi \le 1.0$) between 34 menstrual disorders, endometrial disorders, uterine/tubal blockage, and hormonal 35 disruption with infection-associated symptoms, such as vaginitis, cervicitis, pelvic 36 inflammatory disorder (PID), dyspareunia, tuberculosis (TB), urinary tract infection 37 (UTI), sperm, and semen abnormalities. 38

39 Conclusions: Our study reveals genital infections to be a significant contributor to 40 female infertility. The questionnaire designed here offers a useful tool for self or clinical 41 assessment and may help in timely prognosis/diagnosis of genital infections which 42 may contribute to improved management of reproductive health and fertility.

43

44	Keywords: Female infertility, genital infections, female genital tuberculosis (FGTB),
45	menstrual disorders, PCOS & PCOD, Uterine and tubal blockage, endometrial
46	disorders, endometriosis.

47

Synopsis: The study reveals impact of genital infections on female infertility and offers
a comprehensive questionnaire-based tool for an early self/clinical prognosis of
infection induced infertility.

51

52 Introduction:

Infertility and menstrual disorders are some of the major health concerns affecting 53 women worldwide. A recent report by WHO estimates, that approximately 1 in 6 54 women (17.5% of the adult population) are affected by infertility [1-3], and the rates of 55 infertility are comparable across low-, middle- and high-income countries [3]. The 56 significant number of individuals impacted by infertility, menstrual disorders, and 57 58 reproductive tract anomalies highlights the necessity to broaden the availability of reproductive health care and prioritization of this matter in health research and policy 59 60 [3]. This will ensure the availability of secure, efficient, and reasonably priced treatment modalities for women suffering from these disorders and couples desiring to become 61 parents [2, 3]. 62

Infertility is a disease of both the male and/or female reproductive system and 63 is defined as the inability to conceive after a year of regular, unprotected sexual 64 intercourse [2, 3]. It is a complex and multi-factorial disorder that can result from 65 numerous factors such as genetic, environment, nutrition, infections, and lifestyle [4]. 66 In the absence of regular reproductive health assessment due to cultural/financial 67 constraints and societal stigma, reproductive health issues remain largely ignored. 68 This leads to delayed diagnosis and treatment of these disorders causing infertility in 69 the long run [2]. Infertility has the potential to cause substantial emotional and 70 71 economic strain on the families and impacts individuals' mental and psychosocial welfare. Countless individuals encounter overwhelming medical expenses during 72 infertility treatments, leading to healthcare-induced poverty [2, 5-7]. 73

In tropical countries like India, where tuberculosis (TB) and other infectious diseases are widespread, the role of infectious diseases in causing infertility becomes a prominent consideration as indicated by several studies [5, 8-10]. Genital infections

(sexually transmitted, postpartum, post-abortion infections and secondary infections 77 e.g., TB) may cause a wide spectrum of conditions like vaginitis, cervicitis, 78 dyspareunia and PID [11, 12], endometriosis and other endometrial disorders [5, 13], 79 PCOS/PCOD, ovarian atresia or cysts and anovulation [14, 15]. These infections are 80 generally chronic in nature and cause inflammation and irreversible scarring of the 81 reproductive tract leading to sub-fertility, infertility, recurrent abortions, low birth weight, 82 83 pre-term birth, stillbirth, maternal and infant mortality [5, 9, 10]. For instance, female genital tuberculosis (FGTB) is estimated to be responsible for 6-25% of female 84 85 infertility cases in India [5, 16-19]. FGTB can occur as a primary infection or as a result of secondary spread from infected lungs or reactivation of the latent infection and may 86 cause reduced ovarian reserve (ovarian atresia), PCOS/PCOD, fallopian tube, and 87 uterine damage (e.g. adhesions, cysts and endometrial disorders), pregnancy failures 88 and infertility. The treatment of FGTB involves a combination of anti-TB drugs and 89 surgical intervention(s), however, the success rates of these treatments in terms of the 90 improvement in fertility vary depending on the severity of the reproductive tract 91 damage [20-22]. Previous research also links bacterial vaginosis (BV) to PID and 92 endometritis with consequential infertility [11]. Endometrial presence of BV-related 93 bacteria is connected to 3.4 times higher infertility risk [13]. Women with subclinical 94 PID show 40% lower pregnancy chances compared to those without it [12]. 95

96 Substantial clinical evidence exists for the role of infections in infertility from 97 investigational surveys involving confirmatory tests. However, questionnaire-based 98 surveys for female infertility do not typically include queries regarding infection-99 associated symptoms which can be self/clinically assessed. Hence, to understand the 100 landscape of infertility and the influence of infections on various reproductive health 101 parameters among female subjects in the rural setup, we designed a detailed

questionnaire that specifically addresses the gaps listed above by the inclusion of 102 detailed gueries on infection-associated symptoms. We then conducted an 103 observational, cross-sectional survey at an OB & GYN hospital (mother and child care 104 hospital) in Warangal, India. The subjects included were mainly from rural and semi-105 urban backgrounds. Our study provides evidence for usefulness of the questionnaire 106 designed by us as a valuable tool for self or clinical assessment of female reproductive 107 108 health and may help in timely prognosis/diagnosis of genital infections which may further improve the management of reproductive health and fertility. 109

110

111 Materials and Methods

112 Ethics statement

The research was conducted in accordance with the ethical guidelines set forth by the 113 Indian Council of Medical Research (ICMR) for biomedical and health research 114 involving human participants [23]. The study was approved by the Institutional Human 115 Ethics Committee (IHEC) of Birla Institute of Technology and Sciences (BITS) Pilani 116 Hyderabad campus (Protocol number: BITS-HYD/IHEC/2022/01). All individuals who 117 participated in the study were fully informed about various aspects, including the 118 study's objectives, methodologies, sources of funding, potential conflicts of interest, 119 institutional affiliations of the researcher, anticipated benefits, potential risks, and the 120 discomfort they might experience. Their participation was contingent on obtaining their 121 informed consent. Furthermore, to safeguard patient confidentiality, we took measures 122 to de-identify patient information. This included the removal of exact ages, which were 123 replaced with age ranges, and the omission of exact dates or photographs during 124 presentation of the data (See Supplementary Material 1 for patient consent form). 125

126

127 Study design, inclusion/exclusion criteria, and enrolment

The observational, cross-sectional survey was conducted in Curewell Hospital, 128 Warangal, Telangana, India. Subject recruitment for the study was done based on the 129 gynecologist's assessment. Subjects were enrolled in the study based on the 130 inclusion/exclusion (I/E) criteria. In this study, female subjects (18-45 years) visiting 131 the clinic for infertility treatment (along with their male partners) were enrolled. Female 132 subjects outside the age group of 18-45 years were excluded from this study. Subjects 133 (couples) with complaints of infertility (not getting conceived for a duration of ≥ 12 134 135 months) were classified into the infertile group. Infertile subjects were further stratified into primary (no live birth) and secondary infertility cases (at least one live birth). 136 Females with regular menstrual cycles and no recent history of infertility or genital 137 infection were classified into the healthy control group. Subjects diagnosed with 138 Human Papillomavirus (HPV), Human Immunodeficiency virus (HIV), and Hepatitis C 139 virus (HCV), and/or undergoing any antibiotic or hormonal therapy or in vitro 140 fertilization (IVF) treatment, were excluded from this study. 141

142

143 Study Population and questionnaire-based data collection

The sample size (n = 97) was determined by the help of formula n=[DEFF * Np(1-144 p)]/[($d^2/Z^2 + \alpha/2^*(N-1) + p(1-p)$], where n = sample size, DEFF = design effect, N= 145 population size (10^7), p = estimated proportion ($6.7\% \pm 5$), q= 1-p, d = desired absolute 146 precision (5%) or absolute level of precision, achieving a confidence level of 95% [24, 147 25]. Hence, a total of 100 female subjects were enrolled for this study based on I/E 148 criteria defined above following the informed consent. These subjects were further 149 allocated into groups (infertile and healthy) based on their fertility status (Figure 1 for 150 study outline). The subjects in each group were assessed on a single time-point using 151

a detailed questionnaire. The questionnaire (**Supplementary Material 2**) is designed to collect a comprehensive data on the female subjects included a variety of parameters (**Supplementary Material 3, Table S1**). The study solely assessed the existing information provided by the subjects (including previous test reports) and did not involve collection of any new samples or performance of any new tests.

157

Data handling and statistical analysis. The data was collected through 158 questionnaire followed by digital recording into Microsoft (MS) Excel sheet via Google 159 160 forms. For the purpose of analysis, the data sets were simplified into a multinomial format (Yes/No/No data). Data was plotted using MS Excel. Data analysis for 161 calculation of the frequency distribution and correlation (Phi coefficient) was performed 162 using IBM SPSS Statistics for Windows, Version 25.0., IBM Corp., Chicago, ILSPSS 163 amongst multiple parameters listed in Table S1. Data is reported as per the 164 STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) 165 guidelines (https://www.strobe-statement.org/). 166

167

168 **Results**

Landscape of female Infertility and other reproductive health-related conditions 169 A comprehensive questionnaire-based cross-sectional study is carried out to identify 170 171 the most significant parameters associated with subfertility, infertility (primary and secondary), or conditions like pre-term birth, spontaneous abortions, medical 172 termination of pregnancy, and ectopic pregnancy in females. Out of the 100 subjects 173 assessed, 62 were categorized into the infertile group and 38 were healthy subjects 174 with no history of infertility or menstrual disorders (Figure 1). Amongst the infertile 175 group, only female infertility (39%) with healthy and fertile male spouses, 176

predominated the assessed population (Figure 2A). Infertility due to only male factors 177 with apparently healthy/fertile females represented only 2% of the study population 178 (Figure 2A). Female infertility is seen in 60% of the total study population including 179 21% of cases contributed by both male and female infertility (Figure 2A). Out of the 180 total 62 infertility cases, 90% are diagnosed with primary infertility, rest 10% are cases 181 of secondary infertility (Figure 2B). Our study highlights an early onset of female 182 infertility as young as \leq 20 years of age (Figure 2C), with predominance of both 183 primary and secondary infertility in the age group of 21-30 years (Figure 2C). Among 184 185 62 infertility cases, ~74% failed to conceive even once, and a large proportion of ~23% suffered from spontaneous abortions/have undergone medical termination of 186 pregnancy (MTP) (Figure 2D). Ectopic pregnancies were also observed in ~3% of 187 cases, however, no pre-term birth cases were observed in this study population 188 (Figure 2D). Age distribution of these failed pregnancies, reveals an early occurrence 189 in the age group of 21-25 years (Figure 2E). 190

191

192 Genital infections- a major but neglected contributor to female infertility

Among the various parameters assessed in females belonging to the infertility group, 193 incidence of genital infections (symptomatic and/or confirmed diagnosis) were 194 thoroughly investigated in this study, such as vaginitis (vaginal itching, burning and 195 196 discharge), PID, confirmed/symptomatic cases of UTIs (painful micturition/burning sensation on micturition), TB positivity (based on tuberculin test/ QuantiFERON-TB 197 Gold/TB molecular diagnosis using PCR or TB culture test), cervicitis (cervical 198 199 inflammation) and dyspareunia (painful intercourse) (Table S1 and S2A). Surprisingly, a large proportion of ~27% of infertile females show one or more signs of 200 infection-related symptoms (Figure 3A, Table S2A). The major symptoms observed 201

in these subjects are vaginitis (~18%), PID (~26%), dyspareunia (~11%), and 2 202 confirmed cases of pulmonary TB (~3.2%) (Figure 3B, Table S2A). Interestingly, the 203 analysis of questionnaire data reveals that confirmatory detection of infections has 204 largely been overlooked and is not typically included in the routine check-ups involved 205 in infertility management. The diagnosis is simply based on visible signs of genital 206 infections listed above. Hence, the detection of genital infections may prove to be a 207 208 highly valuable prognostic and diagnostic marker with significant relevance in the early management of female infertility. 209

210 Menstrual Health- a non-invasive prognostic marker of infertility

Menstrual irregularities appear to be the predominant symptoms observed in the case 211 of females in the infertile group (~42%, Figure 4A, Table S2A and S2B). Menstrual 212 irregularities were further stratified into various categories such as menorrhagia (heavy 213 and prolonged bleeding), dysmenorrhoea (painful periods with cramps), amenorrhoea 214 (absence of periods), metrorrhagia (spot bleeding in between the periods) and 215 oligomenorrhoea (irregular periods or inconsistent blood flow). Among these 216 symptoms, amenorrhoea (~13%), metrorrhagia (~8%), and oligomenorrhoeae (~15%) 217 were evident only in the case of infertile subjects (Figure 4B, Table S2A and S2B). 218 However, symptoms such as menorrhagia (~34% vs. ~24% in infertile vs. healthy) and 219 dysmenorrhoea (~65% vs. ~29% in infertile vs. healthy) were observed both in healthy 220 221 and infertile subjects, though a larger proportion is observed in the infertile group (Figure 4B, Table S2A, and S2B). 222

223

224 Influence of physical health and lifestyle on infertility

Out of the 100 subjects, 63% of women report a lack of exercise in their daily routine.

226 On further stratifying the data based on fertility status, a larger proportion of infertile

females (n = 40, 65% of the infertile group) reported lack of exercise (Figure 5A, Table
S2A). On further looking into the BMI status, all the females with low BMI (BMI < 18,
7% of the total study population) are infertile. Amongst the high BMI population, 10%
are infertile (Figure 5B, Table S2C).

- 231
- 232

233 Spectrum of reproductive tract anomalies in infertile females

We next assessed the spectrum of anomalies in the female reproductive tract in 234 235 infertile subjects. Among the various anomalies, PCOS and PCOD are the most prominent pathological sequelae observed in infertile subjects (n = 19, -31%) (Figure 236 6, Table S2A). The other prominent symptoms include fallopian tube blockage (n = 5, 237 \sim 8%) and a variety of endometrial disorders, such as secretory/proliferative/thickened 238 endometrium/hyperplasia/cysts (n = 4; \sim 7%), and endometriosis (n = 2, \sim 3%) (**Figure** 239 6. Table S2A). Unlike these symptoms, only one case of anovulation and ovarian 240 teratoma is observed in the infertile group (Figure 6, Table S2A). 241

242

243 Hormonal perturbations in infertile females

We next attempted to understand the changes in reproductive hormones in women 244 experiencing infertility. We compared and categorized the hormonal profiles of the 245 infertile subjects into low, high, and normal in the case of luteinizing hormone (LH) and 246 follicle-stimulating hormone (FSH). In the case of anti-Mullerian hormone (AMH) and 247 prolactin, data was stratified into abnormal (high) and normal. In the majority of the 248 cases, data for hormone profiles is not available (Table S2D). Although 58% of the 249 infertile subjects were tested for FSH, no specific pattern is observed concerning 250 infertility (Figure 7, Table S2D). For other hormones, data is available only in < 23% 251

of the infertile subjects, and no conclusive inference concerning fertility status could
be drawn (Figure 7, Table S2D).

254

255 Male infertility and semen abnormalities in the infertile group

Among the 62 infertile couples, a large proportion of male counterparts (n = 23, 37%) 256 presented with a variety of semen abnormalities (Figure 8A), such as, oligospermia 257 258 (low sperm count), low sperm DNA integrity (SDI), asthenozoospermia (AS) or low sperm motility, teratozoospermia (high TZI index > 1.6) indicating presence of 259 260 abnormal shaped sperms (often linked with infection, injury or smoking), pyospermia (presence of pus cells in semen), hypospermia (low volume of semen) and 261 hyperviscosity (Figure 8B, Table S2A). The most predominant abnormalities are 262 oligospermia (21%), asthenozoospermia (23%), and teratozoospermia (~ 15%). A few 263 cases of pyospermia (8.1%) and hyperviscosity (5%) are also observed indicative of 264 infection or high levels of seminal leukocytes (Figure 8B, Table S2A) also indicated 265 previously [26, 27]. 266

267

268 Multivariate correlation analysis among various parameters

The major objective of this study is to identify the most significant parameters (**Table** 269 **S1**) that impact fertility and reproductive health in females. We also wanted to assess 270 271 if changes in these critical female parameters co-occur/correlate with the reduced sperm/semen quality in males. We stratified the parameters into various categories 272 such as (a) menstrual disorders (Table S2A and S2B), (b) reproductive tract 273 anomalies such as endometriosis, other endometrial disorders 274 (e.g. thickened/secretory/proliferative endometrium/hyperplasia/cysts), fallopian tube or 275 uterine blockages, PCOS/PCOD, anovulation and ovarian cysts/teratoma (Table 276

S2A), (c) genital infection associated symptoms/confirmed diagnosis of infections like
TB/UTIs (Table S2A), (d) physiological parameters such as reproductive hormones
(FSH, LH, Prolactin, AMH) (Table S2D), (e) physical parameters and lifestyles, such
as weight, height, BMI and exercise routine (Table S2A and S2C) and (f) male sperm
and semen abnormalities (Table S2A). To derive the correlations between various
parameters, we performed multivariate correlation analysis (Phi correlation) [28-30].

283 We observe a highly significant and very strong correlation between parameters related to genital infection-associated symptoms (or confirmed diagnosis) and 284 285 menstrual disorders such as oligomenorrhoea, amenorrhoea, metrorrhagia, and dysmenorrhoea. (Figures 9 and 10). Further, a very strong and significant correlation 286 was observed between genital infections and perturbations in the female reproductive 287 hormones such as LH (Figures 9 and 10). The presence of infection-associated 288 symptoms also is strongly correlated with the occurrence of PCOS and PCOD, uterine 289 and tubal blockage, ovarian cysts, and endometrial disorders (Figures 9 and 10). 290

We next assessed if female genital infections correlate/co-occur with 291 abnormalities in the male semen and sperm profile. Our study suggests a very strong 292 and significant correlation of female genital infections with the occurrence of 293 teratozoospermia, pyospermia, and hyperviscosity of semen and a strong correlation 294 with asthenozoospermia. The abnormalities observed in male partners of infertile 295 296 females in this study concur well with the previously reported sperm abnormalities during male genital infections [26, 27], however, no confirmatory diagnostic reports 297 were available to verify the nature of infections in these males (Figure 9 and 10). 298 299 Another key finding is a very strong and significant correlation between male semen/sperm abnormalities characteristic of infections, such as low sperm DNA 300 integrity, asthenozoospermia, teratozoospermia, pyospermia and hyperviscosity with 301

female disorders such as occurrence of PCOS and PCOD, uterine and tubal blockage,
oligomenorrhoeae, amenorrhoea, metrorrhagia & dysmenorrhoea (Figure 9 and 10).
These observations highlight that transmission of genital infections between sexual
partners could potentially influence female menstrual health and fertility in both males
and females. Male factors are also strongly correlated with hormonal perturbations in
infertile females such as FSH, LH, and AMH (Figures 9 and 10).

308 Among other parameters, we observe a strong and significant correlation between reproductive tract anomalies such as PCOS and PCOD with the occurrence 309 310 of menstrual disorders such as amenorrhoea (Figures 9 and 10). We also observe endometrial disorders to impact menstrual health and are significantly correlated with 311 menorrhagia. We next assessed if the reproductive tract anomalies are linked with 312 reproductive hormones. We observe a strong and significant correlation between 313 ovarian cysts with AMH and anovulation with FSH, LH, and prolactin (Figures 9 and 314 **10**). In addition, uterine and tubal blockage are strongly correlated with prolactin, LH, 315 and AMH levels (Figures 9 and 10). However, one limitation of the data collected was 316 the absence of reports corresponding to female reproductive hormones in a large 317 number of cases (Figure 7, Table S2D). 318

Peculiarly, we observe a very strong and significant correlation between BMI in females and genital infection-associated symptoms (such as dyspareunia/cervicitis/vaginitis), menstrual disorders (such as menorrhagia), and reproductive hormones (such as LH) (**Figure 9 and 10**).

323

324 Discussion & Conclusion

325 Remarkably, our investigation revealed that genital infections are often 326 overlooked during pregnancy or in women of reproductive age, indicating a glaring

gap in current healthcare practices and a significant lack of robust point-of-care (POC) 327 diagnostic tools in rural areas for detecting genital infections, including TB. Hence, 328 infertile women are typically treated primarily with hormones (Letrozole or clomiphene) 329 to improve ovulation, hormonal stimulation, and improvement of menstrual health and 330 are not treated for infections unless there are visible signs. As a result, asymptomatic 331 females remain undiagnosed for infections and do not receive appropriate health care 332 333 promptly. This prolonged lack of diagnosis and treatment can lead to chronic infections and consequential pathological sequelae, ultimately resulting in infertility. 334

335 One of the most striking revelations from our study was the early onset of infertility, occurring between 18 to 25 years of age. This suggests that many affected 336 individuals might have experienced mild or chronic symptoms post-puberty, which 337 remained undiagnosed and untreated. Importantly, a substantial portion of these 338 patients exhibited classical signs of infection (27%), while 73% were rendered 339 ineligible for confirmatory diagnostic tests due to a lack of classical symptoms of 340 infections. This underscores the urgent need for more comprehensive screening 341 strategies. We then uncovered a range of reproductive tract anomalies in infertile 342 females, including signs of PCOD/PCOS, tubal blockage, and smaller percentages 343 with conditions such as endometriosis, anovulation, uterine fibroids, and ovarian cysts. 344 This diversity of conditions makes it challenging for clinicians to establish a clear link 345 between these disorders and genital infections. 346

Furthermore, we observed a very strong and significant correlation between genital infections and both physiological (hormonal profiles and BMI) and pathological effects on female reproductive health (reproductive anomalies and menstrual disorders) and sperm/semen quality in the case of males. Hence, detecting and treating these infections is crucial not only for improving female reproductive health

but also for enhancing the success rate of fertility treatments, including assisted reproductive technologies (ART). This suggests a potential link between poor lifestyle habits and these health issues, similar to associations found with diabetes, obesity, and PCOS/PCOD [31, 32].

Diagnosing genital infection in case of TB, BV, candidiasis, PID, and 356 endometritis can be challenging due to varying, mild, or absent symptoms [13]. 357 Moreover, identifying upper reproductive tract pathogens (endometrial/tubal/ovarian) 358 through microbial culture could be challenging requiring invasive sampling and there 359 360 is also the risk of vaginal and/or cervical pathogens contaminating these samples [13, 20-22]. Therefore, a modest clinical suspicion of genital infection is critical to identify 361 women at risk to prompt them for further detailed clinical investigations [33]. The 362 comprehensive questionnaire or survey-based approach as designed by us in this 363 study could address this gap and help in patient stratification for downstream 364 confirmatory diagnosis and treatments. On confirmatory diagnosis, treatment for 365 infections using suitable antimicrobials has shown benefits in terms of improving 366 symptoms and fertility outcomes [20-22, 34, 35]. Asymptomatic patients with chronic 367 endometrial disorders and unexplained infertility, recurrent implantation failures, 368 miscarriages, or intrauterine infections in previous pregnancies (like chorioamnionitis 369 370 or deciduitis), should also be considered for confirmatory diagnosis for infections.

Hence, we stress the potential of utilizing questionnaires for self/clinical assessment, possibly through survey forms/user-friendly phone or web applications in regional languages. This innovative strategy will also empower women from various backgrounds to report reproductive health issues at an early stage, leading to timely diagnosis and treatment thereby preventing chronic infections and long-term damage in the form of infertility. This may also prevent medical poverty associated with

exorbitant treatment costs linked with ART. Our study also highlights an urgent need for improvement in point-of-care (POC) diagnostic tools, increased awareness, and a more holistic approach to tackle genital infections in the context of infertility. By bridging these gaps, we can make significant strides in enhancing reproductive health outcomes for women in rural and semi-urban settings, especially low and middle income countries, promoting overall well-being and fertility.

383 Author Contribution

NP and RJD have conceived and designed the project, performed data mining, 384 385 analyzed the results, designed figures as well written and edited the manuscript. NP collected the data at the clinic. US (epidemiologist) performed the statistical analysis. 386 RJD (microbiologist and biochemist), MJ (medical microbiologist), and VH (OB & 387 Gynaecologist, Curewell Hospital) provided overall supervision and coordination 388 during data collection at the clinical site. VH contributed to the enrolment of subjects 389 and patient stratification based on their fertility status. RJD received the funding. All 390 the authors reviewed and edited the manuscript. 391

392

393 Funding

394 Source of financial support in the form of grants:

Indian Council of Medical Research (ICMR), Govt. of India, Senior Research
 Fellowship (RBMH/FW/2019/13) awarded to Naresh Patnaik (2019-2022).

2. Research Initiation Grant (RIG) and Centre for Human Disease Research (CHDR)

³⁹⁸ programs intramurally funded by Birla Institute of Science and Technology (BITS)

Pilani, Hyderabad campus, India to Ruchi Jain Dey (June 2018- March 2023).

3. Ramalingaswami Re-entry fellowship (BT/RLF/Re-entry/18/2016) awarded to
Ruchi Jain Dey (May 2018- April 2023).

402	
-----	--

403 Acknowledgments

- RJD and NP are thankful to Amancha Sireesha for technical support and to the medical
- staff at Curewell Hospital for support during the primary assessment and stratification
- 406 of subjects.
- 407

408 Data availability statement

- All data that supports the findings of this study are available from the corresponding
- 410 author upon reasonable request.

411

412 **Conflict of Interest Statement**

413 The authors declare no conflict of interest.

414

- 415 **Supplementary Materials:** Supplementary materials contain the following:
- 416 Supplementary Material 1 Patient consent form
- 417 Supplementary Material 2 Patient Questionnaire
- 418 Supplementary Material 3 Tables S1-S2 (A, B, C and D)

419

420 References

- 421 [1] Halleran M, Chernoff A, Gordon JL: Fertility Knowledge Among Women Struggling
- 422 to Conceive Without Medical Intervention: A Brief Report. *Front Glob Womens Health*
- 423 2022;3: 828052.
- 424 [2] Njagi P, Groot W, Arsenijevic J, Dyer S, Mburu G, Kiarie J: Financial costs of
- 425 assisted reproductive technology for patients in low- and middle-income countries: a
- 426 systematic review. *Hum Reprod Open* 2023;2023(2): hoad007.
- 427 [3] WHO. https://www.who.int/news/item/04-04-2023-1-in-6-people-globally-affected-
- 428 <u>by-</u>
- 429 infertility#:~:text=Large%20numbers%20of%20people%20are,report%20published%
- 430 <u>20today%20by%20WHO</u>. Published 2023. Accessed 4th April 2023.
- 431 [4] Wu J, Li D, Liu X, Li Q, He X, Wei J, et al.: IDDB: a comprehensive resource
- 432 featuring genes, variants and characteristics associated with infertility. *Nucleic Acids*
- 433 *Research* 2020;49(D1): D1218-D1224.
- 434 [5] Sharma JB, Dharmendra S, Agarwal S, Sharma E: Genital tuberculosis and
 435 infertility. *Fertility Science and Research* 2016;3(1): 6.
- 436 [6] Deshpande PS, Gupta AS: Causes and prevalence of factors causing infertility in
- 437 a public health facility. *Journal of human reproductive sciences* 2019;12(4): 287.
- 438 [7] Allsworth JE, Peipert JF: Prevalence of bacterial vaginosis: 2001–2004 national
- health and nutrition examination survey data. *Obstetrics & Gynecology* 2007;109(1):
 114-120.
- [8] Dyer SJ, Patel M: The economic impact of infertility on women in developing
 countries-a systematic review. *Facts, views & vision in ObGyn* 2012;4(2): 102.
- [9] Saigal K, Dhawan B, Rawre J, Khanna N, Chaudhry R: Genital Mycoplasma and
- 444 Chlamydia trachomatis infections in patients with genital tract infections attending a

tertiary care hospital of North India. *Indian Journal of Pathology and Microbiology*2016;59(2): 194.

[10] Dhawan B, Khullar S, Rawre J, Gupta S, Khanna N: Prevalence of genital
Chlamydia trachomatis at a tertiary care hospital in North India: A 10-year
observational study. *Indian Journal of Sexually Transmitted Diseases and AIDS*2023;44(1): 104.

[11] Haggerty CL, Totten PA, Tang G, Astete SG, Ferris MJ, Norori J, et al.:
Identification of novel microbes associated with pelvic inflammatory disease and
infertility. *Sexually transmitted infections* 2016;92(6): 441-446.

[12] Wiesenfeld HC, Hillier SL, Meyn LA, Amortegui AJ, Sweet RL: Subclinical pelvic
inflammatory disease and infertility. *Obstetrics & Gynecology* 2012;120(1): 37-43.

[13] Cicinelli E, Matteo M, Tinelli R, Lepera A, Alfonso R, Indraccolo U, et al.:
Prevalence of chronic endometritis in repeated unexplained implantation failure and
the IVF success rate after antibiotic therapy. *Human reproduction* 2015;30(2): 323330.

[14] Jirge P, Chougule S, Keni A, Kumar S, Modi D: Latent genital tuberculosis
adversely affects the ovarian reserve in infertile women. *Human Reproduction*2018;33(7): 1262-1269.

463 [15] Jirge PR: Effect of genital tuberculosis on ovarian reserve. US Endocrinology
464 2020;16: 104-108.

[16] Sharma J, Sharma E, Sharma S, Dharmendra S: Recent advances in diagnosis
and management of female genital tuberculosis. *The Journal of Obstetrics and Gynecology of India* 2021;71(5): 476-487.

[17] Zahoor D, Bhat MM, Kanth F, Farhana A: Prevalence of genital tuberculosis in
infertile women; a study from a Tertiary Care Center in North India. *IJCMR* 2019;6(6):
F1-F3.

[18] Agarwal S, Chauhan J, Vacchani A, Ahir KK: A study on co-relation of infertility
and female genital tuberculosis. *National Journal of Medical Research* 2016;6(02):
151-154.

[19] Sharma D, Depan A, Yadav K, Narayan S, Sharma A: Prevalence of female genital
tract tuberculosis in suspected cases attending Gynecology OPD at tertiary centre by
various diagnostic methods and comparative analysis. *International Journal of Reproduction, Contraception, Obstetrics and Gynecology* 2019;8(6): 2286-2293.

[20] Sharma JB, Sharma E, Sharma S, Dharmendra S: Female genital tuberculosis:

479 Revisited. *The Indian journal of medical research* 2018;148(Suppl 1): S71.

480 [21] Tripathy SN, Tripathy SN: Infertility and pregnancy outcome in female genital

tuberculosis. *International Journal of Gynecology & Obstetrics* 2002;76(2): 159-163.

[22] Tripathy S. Tuberculosis manual for obstetricians & gynecologists. JP Medical Ltd.2015.

484 [23] ICMR. National ethical guidelines for biomedical and health research involving
485 human participants. In: Unit IB, ed. New Delhi: Director General ICMR. 2017.

[24] Patra S. Female Infertility in India: Causes, Treatment, and Fertility Impairment in

487 High Prevalence Districts. PAA 2017 Annual Meeting: PAA. 2017.

[25] Scheaffer RL, Mendenhall III W, Ott RL, Gerow KG. Elementary survey sampling.
Cengage Learning. 2011.

490 [26] Moretti E, Capitani S, Figura N, Pammolli A, Federico MG, Giannerini V, et al.:

491 The presence of bacteria species in semen and sperm quality. *Journal of assisted*

492 *reproduction and genetics* 2009;26: 47-56.

- [27] Solomon M, Henkel R: Semen culture and the assessment of genitourinary tract
 infections. *Indian Journal of Urology: IJU: Journal of the Urological Society of India*2017;33(3): 188.
- 496 [28] Akoglu H: User's guide to correlation coefficients. *Turkish journal of emergency* 497 *medicine* 2018;18(3): 91-93.
- [29] Hosseinzadeh-Shanjani Z, Hajimiri K, Rostami B, Ramazani S, Dadashi M:
 Stress, anxiety, and depression levels among healthcare staff during the COVID-19
 epidemic. *Basic and Clinical Neuroscience* 2020;11(2): 163.
- [30] Kerur BM, Bhat BV, Harish B, Habeebullah S, Kumar CU: Maternal genital
 bacteria and surface colonization in early neonatal sepsis. *The Indian journal of pediatrics* 2006;73: 29-32.
- [31] Sedighi S, Akbari SAA, Afrakhteh M, Esteki T, Majd HA, Mahmoodi Z: Comparison
- 505 of lifestyle in women with polycystic ovary syndrome and healthy women. *Global* 506 *journal of health science* 2015;7(1): 228.
- ⁵⁰⁷ [32] Lim SS, Hutchison SK, Van Ryswyk E, Norman RJ, Teede HJ, Moran LJ: Lifestyle
- changes in women with polycystic ovary syndrome. *Cochrane Database of Systematic Reviews* 2019(3).
- [33] Gallo MF, Macaluso M, Warner L, Fleenor ME, Hook III EW, Brill I, et al.: Bacterial
 vaginosis, gonorrhea, and chlamydial infection among women attending a sexually
 transmitted disease clinic: a longitudinal analysis of possible causal links. *Annals of epidemiology* 2012;22(3): 213-220.
- [34] Workowski KA, Bolan GA: Sexually transmitted diseases treatment guidelines,
- 515 2015. *MMWR Recomm Rep* 2015;64(Rr-03): 1-137.
- [35] Wiesenfeld HC, Meyn LA, Darville T, Macio IS, Hillier SL: A randomized controlled
- 517 trial of ceftriaxone and doxycycline, with or without metronidazole, for the treatment of

- acute pelvic inflammatory disease. Clinical Infectious Diseases 2021;72(7): 1181-
- 519 1189.
- 520
- 521

522 Figures

Figure 1. Study design flowchart. The figure depicts an outline of the cross-sectional survey conducted on infertile and healthy women to understand various parameters influencing female fertility. In this study, 45 parameters (listed in Table S1) were assessed to determine the frequency distribution and Phi correlation between different parameters (as described in Table S2A-D and Figure 9, respectively).

528

Figure 2. Population distribution and pattern analysis of female infertility and 529 530 other reproductive conditions. A. Pie-chart shows the population distribution of infertility amongst the assessed subjects (n = 100, 62 infertile couples, and 38 healthy 531 subjects). Out of 62 infertile couples, 60 cases were found to be associated with female 532 infertility (39 cases of only female infertility and 21 cases of both male and female 533 infertility), while 2 cases were identified as only male infertility leading to failure in 534 conception. B. Histogram shows the percentage distribution of primary and secondary 535 infertility amongst the 62 cases of infertility. C. Histogram shows the age-based 536 percentage population distribution (females) of primary and secondary infertility 537 amongst 62 cases of infertility. D. Pie chart shows the percentage population of 538 preterm birth, spontaneous abortions/medical termination of pregnancy (MTP), ectopic 539 pregnancy, and no conception amongst infertile females (n = 62). E. Age-based 540 population distribution of females (n = 62) experiencing preterm birth, spontaneous 541 abortions/MTP, ectopic pregnancy, and no conception. 542

543

Figure 3. Contribution of genital infections to female infertility. A. The Pie chart
shows the percentage of infertile females experiencing symptoms of genital infections
or confirmed diagnosis of infection. Reports suggest tuberculosis infection (based on

PPD tests) in 2 cases out of 62 subjects, while other infections are not identified during diagnosis. B. Histogram shows population distribution of various genital infectionrelated symptoms in females belonging to the infertile group (n =62, all cases of infertility) and healthy group (n = 38). Healthy females do not show any symptoms of infection, hence their bar is represented as "0".

552

Figure 4. Female infertility and menstrual health. A. Histogram shows the percentage population distribution of females with respect to their menstrual health based on the regularity of the menstrual cycle. B. Histogram shows population distribution of various menstrual disorders among females belonging to infertile (n =62, all cases of infertility) and healthy groups (n = 38). Infertile [%] = [No. of patients with symptoms/Total infertility cases] *100. Healthy [%] = [No. of healthy subjects with symptoms/Total no. of healthy subjects] *100.

560

Figure 5. Contribution of lifestyle (exercise) and body mass index (BMI) to female infertility. A. Histogram shows the population distribution of all females (healthy and infertile) based on their exercise routine. B. Histogram depicts the population distribution of all females (healthy and infertile) with respect to their BMI. (Normal BMI:18-25; Low BMI: <18; High BMI > 25).

566

Figure 6. Female infertility and anatomical abnormalities of the reproductive tract. The histogram shows the population distribution of various anatomical abnormalities of the female reproductive tract in infertile (n =62, all cases of infertility) and healthy group (n = 38). Infertile [%] = [No. of patients with symptoms/Total infertility cases] *100. Healthy [%] = [No. of healthy subjects with symptoms/Total no. of healthy

subjects]*100. Healthy females do not show any reproductive anomalies their bar is
represented as "0".

574

Figure 7. Female infertility and hormonal perturbations. The histogram shows the 575 population distribution of females categorized under the infertile group (n = 62)576 experiencing abnormal (high/low) levels of female reproductive hormones such as A. 577 578 FSH and LH; B. Prolactin and AMH. Hormone profiles of healthy subjects were not available and hence were not considered during analysis. FSH [Normal: 4-12 IU/L; 579 580 high > 12 IU/L, low < 4 IU/L]; LH [Normal: 5-15 IU/L,; high > 15 IU/L, low < 5 IU/L]; Prolactin [Normal: ≤ 25 ng/ml; high > 25 ng/ml]; AMH [Normal: < 3 ng/ml; High > 3 581 ng/ml] 582

583

Figure 8. Male infertility and semen abnormalities. A. The histogram shows that 584 male infertility is primarily diagnosed with abnormal semen analysis in the infertility 585 group (n = 62) and healthy group (n = 38). B. Histogram shows the various semen 586 abnormalities prevalent in male infertile patients in the study. Infertile [%] = [No. of 587 male subjects with symptoms/Total infertility cases]*100. Healthy [%] = [No. of healthy 588 subjects with symptoms/Total no. of healthy subjects]*100. Males of healthy group do 589 not show any semen abnormalities and hence in absence of data, their bar is 590 591 represented as "0".


592


Figure 9. Correlation heat map between multiple variables. The data gathered by a questionnaire-based assessment of female patients is used for finding out the correlation amongst the various parameters used for the assessment. A multivariate correlation value (Phi correlation with the significance of correlation $p \le 0.05$) was used


for generating this correlation heat map. (P1-P45 are the various parameters assessedin this study, for description see supplementary table S1).

599


Figure 10. Schematic diagram showing correlation between various fertility parameters and their association with the incidence of genital infections. The correlation between various parameters is depicted schematically with the help of bidirectional arrows of varying thickness corresponding to the strength of correlation between these parameters. The correlations are deduced from the multivariate correlation analysis (Phi correlation and the significance of the correlation). For details, refer to the correlation heat map shown in Figure 9.











В













Reproductive abnormality





А

P44	2	NS.	0.229	S	2	8	S	S	8	S	NS.	NS.	S	8	NS.	2	2	2	S	8	SS	NS NS	8	SS NS	2	2	2	8	0.322	1435	8	0.268	0.559	191.0	0.812		
P43 F	NS	NS	0.295 0	0.221	SN	NS	NS	0.241	0.296	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.261 0	3700	NS	0.354 (0.454 (0.623 (
P42	0.252	NS	0.371 (NS (S	NS	NS	0.438	0.438	NS	NS	0.320	NS	NS		0.504 (NS	0.320	NS	SN	0.248	0.384	0.364	NS	0.375	S	NS	NS	0.738 (111 0	SN	0.679	0.648				5 id=3
P40 F	0.267	ß	NS	0.294	0.308	S	8	0.320	0.320	8	ß	NS	R	S	S	NS.	S	0.383 (NS	8	NS	0.384 (S	S	NS	2	8	8	0.575	0.340	0.205	0.380					2
P39	NS	NS	NS	NS	NS	NS	NS	0.249	0.249	NS	NS	0.249	NS	NS	NS	0.399	NS	NS	NS	NS	NS	0.477	NS	NS	0.463	SN	NS	NS	0.945	0.622	NS					Î	2
P38	NS	0.295	NS	NS	SN	NS	NS	NS	NS	NS	0.295	NS	SN	NS	NS	NS	NS	NS	SN	NS	NS	0.261	NS]								
P37	8	NS	SS	S	8	8	8	NS	8	8	NS	0.260	S	S	0.314	0.394	8	8	S	8	NS	0.406	S	8	0.554	2	8	NS	0.799								self correlation
P36	0.332	NS	NS	NS	SN	NS	NS	NS	0.316	NS	0.311	NS	NS	NS		0.366	0.364	0.550	NS	NS	NS									self co							
P35	NS	NS	NS	NS	0.213	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	SS	0.359									1								
P34	8	NS	ß	NS	8	0.301	NS	NS	NS	8	NS	ß	R	S	0.393	SS	0.327	NS	NS	S	0.285	NS	0.485	NS	SS	8		Ì									
P33	NS	NS	NS	NS	NS	1.000	0.571	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.429	NS	NS	NS	0.377	0.524	0.372	NS												
P30	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	NS	0.398	NS	NS	NS	0.391	NS	NS	NS	NS	NS	0.419	0.415	0.404													8
67d	0.344	NS	S	NS	8	NS	0.320	NS	S	0.320	NS	NS	S	NS.	0.249	0.382	8	8	NS	SS	NS	0.414	0.940				Į.										
P28	0.464	NS	NS	NS	NS	NS	0.438	NS	NS	NS	NS	NS	0.312	NS		0.388	NS	0.798	NS	0.282	0.346	0.749															(90)
17d	0.310	NS	NS	NS	NS	NS	172.0	NS	NS	NS	NS	NS	0.402	NS	NS	NS	NS	NS	NS	NS	NS																t(p >0
P21	NS	NS	0.213	0.368	0.281	NS	NS	0.286	0.286	NS	NS	NS	NS	NS	0.780	NS	NS	0.307	0.406	0.806																	not significant (p > 0.05
P20	NS	NS	NS	0.273	0.264	NS	NS	0.230	0.230	NS	NS	0.230	NS	NS	0.629	0.281	NS	0.364	0.327																		not sig
P19	NS	NS	0.295	0.484	NS	NS	NS	NS	0.490	0.295			5 - 5 5 - 5																8 8 9								
P18	0.471	0.363	NS	0.609	0.269	NS	NS	NS	NS	NS	0.344	NS	NS	NS	NS	NS	NS											2									
μJ	NS	0.295	S	0.221	S	NS	NS	ß	NS	0.704	0.335	NS	NS	NS	NS	0.296																					
P16	NS	NS	NS	NS	NS	NS	0.302	NS	NS	0.438	NS	NS	0.313	NS	NS		1																				0.05
P15	8	SS	SN	NS.	8	S	8	NS	NS	8	S	NS	S	SN																							on), p s
P14	NS	NS	NS	NS	SN	NS	NS	NS	NS	SN	0.700	NS	NS																								correlation), p ≤ 0.05
P13	NS	NS	NS	NS	NS	NS	0230	NS	NS	NS	-	NS																									io Du di
D12	SN	NS	NS	NS	NS	I NS	NS	NS	NS	NS	NS																										@>0.15 (stiong
P11	SN	S NS	NS	NS	NS	0.200	NS	NS	NS	0.492)^@
P10	8	0.208	8	SS	2	S	8	NS I	SS		-	_	_								_	_								_	_						8 4-0
B	0.32(NS	NS	NS	SN	NS	SN	1.000			V—1	s;							-	-	s;							V	4-1								s 2
P 8	0.320	NS	NS	NS	NS	NS	SN						_				_																				≤ 0.05
Ld	8	NS.	8	NS.	200	2																															d.(n
9d	NS	NS	NS	9 NS	0.205								_									_															Ø > 0.25 (Very strong correlation), p
5d	NS	3 NS	1 NS	0.289																					_												png co
P4	8		0.271								_					_												_									leny sti
P3	4 NS	NS																																			0.25 ()
μ	0.204																																				ô
P1		2	~	+	5	10				0	-	2		4	5	9	1		6	0	+	1		6	0		4	5	9	1		6	0	2		4	
•	P1	P2	P3	P4	P5	P6	1q	P8	P9	P10	P11	P12	P13	P14	P15	P16	71 7	P18	P19	P20	P21	P27	P28	P29	P30	P33	P34	P35	P36	P37	P38	P39	P40	P42	P43	P44	

